Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Document series

Draft supplier comparison table

Consultation on the comparison table that presents supplier dossiers side by side. The draft table shows only fields verified from a document the Institute holds, and the consultation was principally concerned with whether a sortable table invites a reading…

Document identifier
CEI-CP-033
Series
Public comment period
Version
1.0
Published
10 Jun 2025
Last reviewed
10 Jun 2025
Next review
10 Jun 2026
Identifier
10.71829/cei.cp.33
Certainty
Not rated
Cycle
2025 Q2
Window
28 Apr 2025 – 28 May 2025
Status
Closed
Submissions
14

§1Consultation and window

§1.1Window

Opened
28 April 2025
Closed
28 May 2025
Duration
30 days
Status
Closed — the disposition is published
Document under consultation
Document series
Submissions received
14

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Does presenting suppliers in a sortable table invite a ranking claim the Institute does not make?
  2. Should a field be shown as unverified, or should the column be absent where verification was not possible for most suppliers?
  3. Is the default sort order defensible, given that any default carries an implication?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The table was ratified with amendments. The default sort is alphabetical, a standing statement above the table records that the ordering is not a ranking, and unverified fields are shown as unverified rather than left blank.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.